Durvalumab (D) Tremelimumab (T) Plus Chemotherapy (CT) in 1L Metastatic NSCLC: Outcomes by Tumour PD-L1 Expression in POSEIDON
JOURNAL OF THORACIC ONCOLOGY(2022)
Key words
Durvalumab,Tremelimumab,POSEIDON
AI Read Science
Must-Reading Tree
Example
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined